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In Vivo Studies of Gd-DTPA-Monoclonal Antibody
and Gd-Porphyrins: Potential Magnetic Resonance
Imaging Contrast Agents for Melanoma
D. Shahbazi-Gahrouei,1,2 M. Williams,2 S. Rizvi,3 and B. J. Allen3*
New tumor-specific contrast agents for clinical imaging
and therapy for cancer are required. To this end Gd-H
(Gd-hematoporphyrin), Gd-TCP (Gd-tetra-carboranylme-
thoxyphenyl-porphyrin), Gd-DTPA-WM53, and Gd-DTPA-
9.2.27 were synthesized and administered by systemic in-
jection to nude mice with human melanoma (MM-138)
xenografts. The biodistribution T1 relaxation times and
magnetic resonance (MR) image signal enhancement of the
contrast agents are presented for the first time and com-
pared for each group of five mice. A change (20%) in T1
relaxation times of water in human melanoma tumor xeno-
grafts was revealed 24 hours after injection of the labeled
immunoconjugate Gd-DTPA-9.2.27. The percent of in-
jected antibody or gadolinium that localized to the tumor
was measured by inductively coupled plasma atomic emis-
sion spectroscopy (ICP-AES) to be approximately 35%. A
higher concentration of gadolinium was achieved com-
pared with nonspecific compounds, indicating selective
delivery of Gd-DTPA-9.2.27 to the melanoma xenografts.
Porphyrin-based contrast agents (Gd-H and Gd-TCP) also
showed significant uptake in melanomas. The uptake of
Gd-TCP by the tumor was sufficient to deliver boron atoms
into the tumor, making possible dual use for both MR
imaging (MRI) and boron neutron capture therapy (BNCT).
The linear relationship found between the paramagnetic
contribution to the relaxation rates and contrast agent
concentration allows quantitative studies of paramagnetic
contrast agent uptake. J. Magn. Reson. Imaging 2001;14:
169–174. © 2001 Wiley-Liss, Inc.
Index terms: MRI; monoclonal antibody; Gd-DTPA; Gd-por-
phyrins; melanoma
MAGNETIC RESONANCE IMAGING (MRI) using varied
pulse sequences provides a sharp contrast between tis-
sues with different intrinsic T1 or T2 relaxation times.
By exploiting the differences in relaxation times, images
have been produced that provide previously unobtain-
able physiologic and mobility information (1). The use of
contrast agents to shorten relaxation times and give
enhanced signal intensity (SI) may extend the potential
of MRI to the diagnosis of currently subclinical tumors.
Two approaches are investigated to increase the speci-
ficity of MR image contrast agents by using metallopor-
phyrins and a monoclonal antibody coupled with Gd-
DTPA.
Porphyrins are a unique class of metal chelating
agents that have shown selective affinity for a variety
of tumors (2). The high water solubility and stability
under physiological conditions (3), low propensity for
causing photoxicity (4), and intracellular localization
in mitochondria for more efficient tumor cell killing
(5) are reasons why these complexes have been used
as tumor-specific contrast agents. Tumor-specific
contrast agents with potential for clinical imaging
and therapy for cancer are Gd-hematoporphyrin
(gadolinium-[18,13-bis (hydroxyethyl)-3,7,12,17-tet-
ramethyl-21H, 23H porphine-2, 18-dipropionic acid])
and Gd-TCP (gadolinium-tetra-carboranylomethoxy-
phenyl-porphyrin).
In a second approach, monoclonal antibodies against
leukemia and melanoma are used. These are chelated
with Gd to form the Gd immunoconjugates Gd-DTPA-
WM53 and Gd-DTPA-9.2.27. These agents are tested in
the nude mice model with a human melanoma (MM-
138) xenograft to investigate their pharmacokinetics.
The biodistribution T1 relaxation times and signal en-
hancement of the contrast agents are presented and
compared.
MATERIALS AND METHODS
Monoclonal Antibodies
Two monoclonal antibodies are used: monoclonal anti-
body 9.2.27 (specific for melanoma cell line MM-138)
and monoclonal antibody WM53 (specific for leukemia
cell line HL-60) as the control.
Tumor-Specific Contrast Agents
The preparation method has been reported by Rizvi et
al. (6) and is a modification of the method of Hnatowich
et al. (7). Cyclic anhydride DTPA (cDTPAa, 0.1 mg) was
dissolved in chloroform (1 mL) and was degassed under
a stream of nitrogen for 1 hour. 9.2.27 antibody solu-
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tion (2 mg, 1mL) was added and the mixture incubated
at 0° C for 45 minutes. The mole ratio of DTPA to 9.2.27
was 20:1. The resulting solution was loaded onto a
PD-10 column, Sephadex GM-25 (10 3 1 cm, Pharma-
cia, Biotech), and eluted with 0.5 M sodium acetate (pH
5.5), collecting 2 mL. The concentration of 9.2.27 in the
final solution was determined by protein estimation as
2 mg/mL.
The DTPA-WM53 conjugate was prepared in a man-
ner similar to that of DTPA-9.2.27.
Conjugates Labeled With Gd
The following is the method used for insertion of gado-
linium (8) and is the optimized procedure.
Gadolinium(III) chloride hexahydrate (1.8 mg) was
dissolved in 1 mL of distilled water. To this solution,
DTPA-9.2.27 (4 mg, 2 mL) was added. The pH was
adjusted to 5 by the addition of 1 M sodium acetate.
After stirring for 1 hour at room temperature, the solu-
tion was added to a PD-10 column and eluted with
sodium chloride (0.15 M, pH 5 5), collecting 1-mL frac-
tions. The fourth and fifth fractions were combined to
yield 2 mL of pure Gd-DTPA-9.2.27 solution (protein
estimate 5 2 mg/mL, [Gd] 5 0.47 mM).
The Gd-DTPA-WM53 compound was prepared in
manner similar to that of Gd-DTPA-9.2.27 (protein es-
timate 5 3 mg/mL, [Gd] 5 0.51 mM).
Porphyrin-Based Contrast Agents
Gd-TCP was synthesized for the first time in this labo-
ratory (9) and (15 mg, 0.010 mmol) was dissolved in 1
mL of cremophor EL (CRM) and 2 mL of 1,2-propanediol
(PrG). This solution was transferred into a 10-mL volu-
metric flask, and a 0.9% saline solution was added to
the mark. This gave a final concentration of 1.0 mM.
Gadolinium(III) nitrate hexahydrate (0.30 g, 0.66
mmol) was dissolved in 2 mL of distilled water. Hema-
toporphyrin powder (0.40 g, 0.66 mmol) was suspended
in 2 mL of distilled water and was added to the gado-
linium solution and refluxed until the solution became
homogeneous. The solution was allowed to cool to room
temperature. This solution was reduced to 1 mL under
reduced pressure with heating. The resulting white
solid was filtered, washed carefully with ice-cold water
(2 3 0.5 mL), and dried in the oven at 80° C.
Injected Dose
The animal studies were approved by the UNSW Animal
Care and Ethics Committee. Seven groups of five mice
were used (age, 6–8 weeks; mean weight, 20 g). Each
group was housed five mice per cage in a humidity- and
temperature-controlled isolated animal house at St.
George Hospital. All mice were fed sterilized standard
mouse chow and water ad libitum.
The human melanoma cell line MM-138, originally
derived from human malignant melanoma, was grown
in tissue culture and injected subcutaneously into both
flanks of nude mice (2.5 3 106 cells, 120 mL).
Three to four weeks after tumor implantation, when
the tumor diameter was 3–5 mm (mean weight of tu-
mors, 200 mg), mice received an intraperitoneal (i.p.)
injection of an MRI contrast agent (discrete compounds
GdCl3, Gd-DTPA, Gd-H, and Gd-TCP, and conjugated
antibody). All contrast agents were diluted in physio-
logical saline to a final concentration as injected in
bolus doses (Table 1). Gd-DTPA-9.2.27 was used as the
specific agent and Gd-DTPA-WM53 was used as the
nonspecific agent. The last group was a control group.
The total injected volume was 200 mL. The animals were
killed by an overdose of pentobarbital sodium 24 hours
post i.p. injection, followed by the removal of critical
organs (tumor, kidney, liver, and spleen). These were
minced for MRI and inductively coupled plasma atomic
emission spectroscopy (ICP-AES) experiments. The
gadolinium concentrations in the tumor and various
organs were measured by ICP-AES using the acid di-
gestion method (10).
In Vivo Proton Relaxation Times (T1)
Determination
The effect of contrast agents on proton relaxation times
was measured in tumors and other harvested organs by
an inversion recovery (IR) pulse sequence technique
using a 7.0 T Varian UNITY Plus (Varian Associated
Inc., CA) with a vertical Oxford Instruments magnet of
bore size 89 mm using a saddle coil (DOTY Scientific
Instruments).
MR Image SI
The enhancement effect of all contrast agents on MRI
signal was investigated. All images were obtained using
the T1-weighted imaging method using the IR pulse
sequence technique, with TI 5 200 msec, TE 5 15 msec,
TR 5 300 msec, 5-mm slice thickness, 3 3 3 cm field of
view (FOV), and a matrix size of 256 3 128. MR image SI
was measured by averaging the individual SIs of five
selected voxels. Variations in coil tuning (performed
manually) caused some changes in SI during the exper-
iments.
Gadolinium Concentration Measurements
All tissues were frozen until used for ICP-AES measure-
ments. The gadolinium content was measured by a
ICP-AES (Applied Research Laboratory, UK) instrument
according to the method of Tamat et al. (10). The
342.249-nm atomic emission line of Gd was chosen for
the ICP-AES analysis. The tissue uptake of Gd was
calculated as a percentage of the injected contrast
agent percentage of injected dose (% I.D.).
Table 1
Injected Doses of Contrast Agents Into Each Group of Nude Mice
Group of
mice Contrast agent
Concentration
Gd (mM)
Injected dose of Gd
(mmol/gbw mouse)
1 GdCl3 1.0 0.01
2 Gd-DTPA 1.0 0.01
3 Gd-TCP 1.0 0.01
4 Gd-H 1.0 0.01
5 Gd-DTPA-9.2.27 0.5 0.005
6 Gd-DTPA-WM53 0.5 0.005
7 Control – –
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RESULTS
General Aspects
All mice tolerated the procedures well, including tumor
growth and response to contrast agents. No adverse
effects were observed after injection of contrast agents
and no animal death was recorded during tumor
growth or postinjection.
T1 Relaxation Times
The effect of contrast agents on proton relaxation times
(T1) was measured in tumors and the other harvested
organs. Table 2 shows the T1 values for organs using
different contrast agents and untreated mice (control).
The plot of T1 values for removed tissues is shown in
Figure 1.
These results reflect the gadolinium concentrations
in the tissues reported above. The high uptake of Gd-
DTPA-9.2.27 by the tumor resulted in approximately
20% change in the T1 relaxation time of the water in
human melanoma xenograft when compared to the T1
value for the control. The nonspecific antibody conju-
gate, Gd-DTPA-WM53, recorded a T1 value similar to
the control. Gd-TCP and Gd-H showed a 16% and 21%
decrease in the T1 value for the tumor, respectively
relative to the control.
MR Image SI
MR image SIs for tumor and removed organs and dif-
ferent contrast agents are shown in Figure 2. In the
control, the MR image SI for tumors was lower than that
recorded for the normal tissues studied. This may re-
sult from the T1 relaxation time for the tumor being
longer than the other normal tissue, which decreases SI
and is consistent with T1 values measured in this work
(Table 3).
Gadolinium Content of Tissues
Figure 3 clearly shows that the highest concentration of
gadolinium in tumor (35%) was achieved using Gd-
DTPA-9.2.27, the antibody conjugate using the specific
antibody. This is consistent with the results of the in
vitro experiments.
In contrast, the lowest uptake (3%) was found for
Gd-DTPA-WM53, the conjugate made using the non-
specific antibody. The antibody has retained its non-
specificity for the melanoma cell upon the attachment
of the chelate and gadolinium ions. Tumor uptakes of
21% and 28% of injected gadolinium were recorded for
Gd-TCP and Gd-H, respectively.
DISCUSSION
Quantitative determination of paramagnetic contrast
agents in tissues will help to obtain optimal MR image
intensity (11). Most commonly, the information is ob-
tained from relative MR image intensity changes. This
method suffers from poor accuracy because the relax-
ivity of the agents in the tissues is generally unknown.
The more direct and accurate method involves killing
and dissecting the animals following administration of
contrast agents. The concentration is then determined
by ICP-AES. In this study we report two in vivo methods
to determine the relative concentration of contrast
agents in tissues following administration, using para-
magnetic chelates and monoclonal antibodies.
Figure 2. MR image signal intensity of tissues 24 hours after
injection of different gadolinium compounds (N55).
Figure 1. In vivo T1 (s) relaxation times of gadolinium com-
pounds in melanoma and in selected organs of nude mice
(N55).
Figure 3. Comparison of biodistribution of the gadolinium
uptakes in melanoma xenografts in nude mice from harvested
organs.
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Paramagnetic chelates using the endogenous por-
phyrin ring as the chelating agent are a promising and
interesting family group of potential MRI contrast
agents (12). Gd-porphyrins were synthesized using TCP
and hematoporphyrin and investigated as MRI contrast
agents.
It is also possible to achieve shortening of T1 in the
tumor xenograft by means of gadolinium-labeled tu-
mor-specific antibody. Essential to this experiment was
the development of a conjugate gadolinium complex.
After forming the protein-DTPA complexes, approxi-
mately four atoms of Gd were bound per molecule of
9.2.27 antibody. This conjugate was used as a melanoma-
specific detection MRI contrast agent.
T1 Relaxation Times
The results showed that the T1 relaxation time of the
tumor was significantly greater than that for normal
tissues. The general theory that T1 values are longer in
tumors was confirmed by this animal study. This dif-
ference is reported to arise from an increase in water
content and the large extracellular volumes of the can-
cerous tissues that elevate the T1 values (13). From the
point of view of comparison between T1 values of tumors
in excised tumor and live tumor tissues, results indi-
cate that the T1 relaxation time is lower in excised tu-
mor tissue than in live animal tissue and may decrease
with time after excision due to further loss of water by
evaporation (14,15).
The decreases in the T1 values of the other discrete
gadolinium complexes were in line with the concentra-
tions of gadolinium absorbed by the tumors. These re-
ductions in T1 values of the tumor upon addition of
contrast agent are highly significant, even though the
concentration of agents used in this study (0.005–0.01
mmol/kg) is much lower than the doses of Gd-DTPA
commonly used as a contrast agent in clinical MRI (0.1
mmol/kg).
As can be seen from Figure 1, all contrast agents
show shortening of the T1 relaxation time in the liver,
except for Gd-DTPA-9.2.27. The most significant de-
crease in T1 relaxation times of the liver occurred when
treated with porphyrin compounds. These results are
consistent with the gadolinium concentrations found in
these organs.
Figure 1 also illustrates that the reduction of T1 re-
laxation times in the kidney using conjugated antibody
agents is less than that of discrete contrast agents. The
most effective modification of T1 was observed in the
kidney after administration of GdCl3. This is probably
due to free gadolinium and its urinary excretion. The
smallest T1 value in the spleen was obtained for Gd-
hematoporphyrin. In contrast, the largest T1 relaxation
time was observed for GdCl3. No significant change in
the T1 value was observed for the other contrast agents.
MRI SI
The enhancement of the MR image SI after injection of
tumor-specific contrast agents causes changes in the
T1 values. The highest SI was observed for the tumor
upon injection of Gd-DTPA-9.2.27, reflecting the short-
ening of T1 relaxation times and the maximum accumu-
lation of the contrast agent in the tumor. The porphy-
rin-based contrast agents, Gd-H and Gd-TCP, showed
good enhancement of the signal of the tumor. The en-
hancement effect of the porphyrin complexes in this
study is in good agreement with that reported previ-
ously by conjugation of Gd-DTPA with porphyrins un-
der in vivo conditions in mice (16). The enhancement
effect of the image intensity of the tumor following ad-
ministration of Gd-DTPA showed the potential applica-
tion of this contrast agent. Although the uptake by the
tumor of GdCl3 was significant, the concentration of
gadolinium in the tumor was too low for signal en-
hancement with this contrast agent.
These results also illustrate the MRI contrast-en-
hancing capabilities of Gd-TCP. This signal enhance-
ment of Gd-TCP is indicative, but not proof of, the de-
livery of boron atoms into the cancer cells. Then Gd-
TCP could be a dual-use compound, as it can enhance
contrast between tumor and normal tissues in MR im-
ages and be potentially effective as an agent for boron
neutron capture therapy (BNCT).
The liver showed the greatest enhancement for both
porphyrin agents and the accumulation of gadolinium
complex in this organ. The high MR image SI was re-
corded in the liver for Gd-DTPA and GdCl3, consistent
with both the T1 relaxation time and the uptake dose
determination. The enhancement recorded in the liver
using these porphyrin compounds was greater than
that for monoclonal conjugated agents. This indicates
the accumulation of the nonimmunoconjugated gado-
linium complexes into the liver rather than the tumor.
Table 2
Average T1 Relaxation Times of Different Organs in Groups of 5 of Nude Mice Xenografted With Human Melanoma*
Contrast agent
T1 relaxation times (s)a
Tumour Liver Kidney Spleen
GdCl3 1.43 6 0.03 0.74 6 0.02 0.85 6 0.01 0.84 6 0.03
Gd-DTPA 1.37 6 0.02 0.77 6 0.01 0.87 6 0.02 0.88 6 0.02
Gd-TCP 1.33 6 0.02 0.78 6 0.02 0.94 6 0.02 0.83 6 0.02
Gd-H 1.26 6 0.01 0.74 6 0.02 0.98 6 0.03 0.71 6 0.03
Gd-DTPA-WM53 1.60 6 0.03 0.80 6 0.02 0.92 6 0.01 0.83 6 0.02
Gd-DTPA-9.2.27 1.23 6 0.04 0.92 6 0.03 0.99 6 0.01 0.88 6 0.02
Control 1.59 6 0.03 0.96 6 0.01 0.99 6 0.04 0.96 6 0.02
*Tissues were removed 24-hr after injection of different contrast agents.
aData are mean 6 SEM of values obtained from five mice.
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The MRI SI in the kidney is lower than that for other
organs (Fig. 2). This is again due to the properties of
renal excretion of gadolinium-based contrast agent as
hydrophilic compounds. The graphs of MR image SI
and harvested organs show the enhancement effect for
two discrete compounds, Gd-DTPA and Gd-TCP. No
significant intensification was observed in the spleen
for the other contrast agents.
Gadolinium Content of Tissue
The gadolinium concentration in tumor and other tis-
sues was measured by ICP-AES, and the results com-
pared with the percent of injected Gd localizing in the
tumor (Fig. 3). The percent of injected specific antibody
or gadolinium (35%) that localized into the tumor was
higher than that reported for other antibodies in a
mouse tumor (1,17). This shows that our antibody con-
jugate has a high potential for use as a contrast agent
for the detection of melanoma.
A higher concentration of Gd was achieved in tumor
than with nonspecific compounds (GdCl3, Gd-DTPA-
WM53), indicating selective delivery of Gd-DTPA-9.2.27
to the melanoma xenografts. Significant Gd accumu-
lated in the liver, spleen, and kidney, probably reflect-
ing clearance and metabolism of the Gd complexes.
Figure 3 also indicated that the uptake of Gd-DTPA in
the tumor was approximately half of that for conjugated
specific antibody, Gd-DTPA-9.2.27. This shows the
benefit of conjugation of Gd-DTPA with a monoclonal
antibody for specific-tumor detection agents. Interest-
ingly, the uptake by the tumor of GdCl3 was significant.
The porphyrin-based compounds also showed their
potential as tumor-specific detection agents. The
amount of boron introduced into the tumor by Gd-TCP
was found to be 24 mg. This compares well with other
values for related complexes (18), is sufficient for BNCT,
and proves the potential application of the Gd-TCP in
the dual roles of MRI agent and boron delivery agent for
BNCT.
Generally, a significant gadolinium complex was re-
tained in the liver except for the antibody conjugates,
Gd-DTPA-9.2.27 and Gd-DTPA-WM53. The liver re-
tained the highest amount of gadolinium for the Gd-
porphyrins. At 24 hours postinjection, the gadolinium
content of Gd-porphyrins was at least two times greater
in the liver than that of Gd immunoconjugates. Some of
the gadolinium found in the liver might represent gad-
olinium dissociated from the DTPA. It is known that free
gadolinium accumulates in the liver and this may ex-
plain some of the high uptake in the reticuloendothelial
organ (19). This is in agreement with results of gadolin-
ium content observations reported by other researchers
(4,20). Significant gadolinium accumulation in the
liver, spleen, and kidney probably reflected clearance
and metabolism of the gadolinium complex (21).
As these results indicate, the smallest amount of gad-
olinium was observed in the kidney at 24 hours postin-
jection. This is due to the properties of gadolinium-based
contrast agents, which are hydrophilic, accumulate in the
extracellular water of the tissues, and have rapid renal
excretion. In this study, 30%–50% of the injected dose
disappeared in 24 hours, which is consistent with rapid
clearance (21). The uptake of gadolinium in the spleen
and kidney showed no significant differences for any of
the gadolinium compounds.
The amount of monoclonal antibody injected per ki-
logram was much greater than the quantities routinely
required in nuclear medicine animal experiments (22).
Given the low percentage of monoclonal antibody local-
izing to the tumor and the hazards of injecting increas-
ing amounts of foreign protein, it is doubtful that much
higher concentrations of gadolinium in the tumor could
be obtained by increasing the amount of antibody in-
jected. Of course, the radioisotopes used in nuclear
medicine limits the application of higher doses of con-
trast agents.
The difference between these data and previous ani-
mal experiments (1,11,13) may arise in differences in
the pulse sequences, dose of Gd-DTPA-mab used, the
type of antibody, and possibly the method of measuring
tissue concentration of Gd.
At what time and to what extent the MRI can be
obtained depends on the accessibility of contrast
agents to the tumors. Other researchers (23,24) found
that the enhancement effect of Gd-DTPA-mab on MRI
continued for 24 or 72 hours after injection. Our results
show a good accumulation of the 9.2.27 conjugate in
tumor at 24 hours postinjection. This means that Gd-
DTPA-9.2.27 is suitable as a diagnostic melanoma con-
trast agent for MRI. Improvement of MRI techniques
and novel contrast agents can also help MRI as a pow-
erful diagnostic modality for malignant and benign tis-
sues.
Table 3
Signal Intensity of Different Organs 24 hr after Injection of Different Contrast Agents
Contrast agent
Signal Intensity*
Tumor Liver Kidney Spleen
GdCl3 48 3 93 5 57 3 58 3
Gd-DTPA 63 4 92 4 70 5 83 5
Gd-TCP 71 3 121 6 40 2 80 4
Gd-H 98 5 140 9 65 4 40 2
Gd-DTPA-9.2.27 105 7 66 3 63 3 55 3
Gd-DTPA-WM53 42 2 77 5 73 5 46 2
Control 42 3 50 3 42 2 70 4
*Data are mean SEM of values obtained from five measurements.
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CONCLUSIONS
Tissue-specific agents are required for improved MRI of
melanomas in regional lymph nodes. We have shown
that MRI with Gd-DTPA-9.2.27 offers the advantage of
tissue contrast enhancement and precise anatomic lo-
calization of the tumors, as a substantial enhancement
effect was observed in nude mice with melanoma xeno-
grafts. Further developments in MRI contrast agents, in
combination with improved imaging techniques, may
lead to novel applications in the diagnostic MRI. In this
study, the pharmacokinetics of a paramagnetic con-
trast agent based on monoclonal antibody 9.2.27 have
been studied in a melanoma tumor xenograft model.
Further investigations will include conjugating higher
numbers of Gd atoms into the chelating agent, using
different monoclonal antibodies, and identifying uptake
time of Gd in tissues.
Gd-TCP also can be used as a dual probe for MRI
contrast agent and as a radiation sensitizer for NCT.
This may facilitate tumor detection and treatment plan-
ning and allow radiologists and radiation oncologists to
better diagnose and define the radiation treatment field.
The ability to easily visualize the contrast agents in the
tumor may also make it possible to optimize timing of
radiation therapy treatments in order to maximize tu-
mor cell kill. These attributes potentially will improve
the safety and efficacy of radiation therapy. Both the
MRI findings and the metal content measurements in
this study are consistent with the previous biodistribu-
tion data that the liver is a major organ responsible for
the active uptake and prolonged elimination of porphy-
rin (4,20).
Overall, with the satisfactory low levels of Gd in the
liver, kidney, and spleen, and good tumor uptake, Gd-
DTPA-mab has considerable promise for further diagnos-
tic applications in MRI. The outcome of this study may
help the design of tumor-specific contrast and chemo-
therapeutic agents. The permeability of macromolecule
tracers, such as Gd-DTPA-mab, may provide tissue up-
take information for both contrast and chemotherapeutic
agents. With current debate on tumor-specific and ther-
apeutic agents for tumor diagnosis and therapy, the per-
meability of macromolecules in tumor tissues is an essen-
tial question that needs to be answered.
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